Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1535374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Technetium-99m-sestamibi has been reported to localize in various tumors. Scintigraphic results for a patient with recurrent Hurthle cell carcinoma of the thyroid whose tumor was imaged with both 99mTc-sestamibi and 201TI, but not with 131I, are presented.
Medical subject headings
- Carcinoma
- Neoplasm Recurrence, Local
- Organotechnetium Compounds
- Thyroid Neoplasms